The WVU Heart and Vascular Institute and WVU Cancer Institute performed West Virginia’s first single-port robotic-assisted thoracoscopic lobectomy.
News|Videos|November 7, 2025
Patient-Reported Outcomes From the SERENA-6 Trial of Camizestrant + CDK4/6 Inhibitor For Emergent ESR1m During First-Line Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer
Author(s)Seth Wander, MD, PhD
Seth Wander, MD, PhD discusses an overview of emerging data and evolving treatment strategies in advanced gastric and gastroesophageal cancers, with a focus on the role of biomarkers in guiding targeted and immunotherapy-based treatment. The presentation highlights clinical trial outcomes, testing considerations, and future directions shaping the personalized management of these patients.
Advertisement
Advertisement
Related to this article
The FDA approval of daraxonrasib was based on data from the phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma.
SOT106 earned an FDA fast track designation for advanced or recurrent soft tissue sarcoma.
The sNDA is supported by VIKTORIA-1 Study 2 data showing that gedatolisib-based regimens approximately doubled median PFS vs alpelisib plus fulvestrant.
Ivonescimab plus chemotherapy significantly improved overall survival vs durvalumab plus chemotherapy in advanced biliary tract cancer.
The pertuzumab biosimilar TQB2440 met equivalence margins for tpCR vs reference pertuzumab in ER/PR-negative, HER2-positive early breast cancer.
An OncLive Scientific Interchange and Workshop examined community integration of bispecific antibodies in multiple myeloma.
Olverembatinib produced progressively deepening cytogenetic and molecular responses in second-line chronic-phase chronic myeloid leukemia.
Advertisement
Advertisement